TITLE

Today's fastest, most efficient sponsors

AUTHOR(S)
Korieth, Karyn; Anderson, Annick
PUB. DATE
September 2014
SOURCE
CenterWatch Monthly;Sep2014, Vol. 21 Issue 9, p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article offers information on the analysis of drug development and the effort of sponsors for fast and efficient development cycle. Among the success factors for clinical development mentioned are focusing resources on key areas, leveraging the capabilities of global development organizations, and simplifying procedures for protocol design. It also mentions optimization of clinical development processes, creation of efficient project teams, and collaborations with regulatory authorities
ACCESSION #
99809395

 

Related Articles

  • Building Automation Systems in a PAT Framework. Whitney, Jonathan T.; Granger, Mark A. // BioPharm International;Sep2005, Vol. 18 Issue 9, p70 

    Reports on the role of building automation technology system in maintaining and validating quality manufacturing environments in the U.S. Provision of closed-loop feedback control and analysis of the process of manufacturing a quality environment with optimum temperature; Details on the...

  • Entrepreneurial Innovation in Pharmaceutical Research and Development. Boyatzis, Richard E.; Esteves, Mary B.; Spencer Jr., Lyle M. // Human Resource Planning;1992, Vol. 15 Issue 4, p15 

    Rapid innovation in pharmaceutical firms, especially in drug development, benefits the consumer and the company. Based on earlier organizational competency studies, a diagnostic study and intervention are detailed here in which the time needed to develop a drug was reduced by over 30%, doubling...

  • Should R&D be the face of your organization? CARRISON, DAN // Industrial Management;Jul/Aug2015, Vol. 57 Issue 4, p6 

    The article offers the author's insights on whether research and development (R&D) should be the forefront of the pharmaceutical organization. Topics discussed include the challenges faced by the managers of pharmaceutical company Pfizer who bought the first cancer drug Sutent, the...

  • Reducing the cost of instrument ownership.  // Life Science Today;Apr2000, Vol. 1 Issue 2, p16 

    Outlines the cost-effective approaches in evaluating process control and analysis instrumentation in pharmaceutical manufacture. Stringency of government regulations in drug development; Need for an independent third-party information to evaluate an instrument's performance; Availability of...

  • Rules of Automation. Koppal, Tanuja // Drug Discovery & Development;Aug2005, Vol. 8 Issue 8, p9 

    Focuses on the significance of automation in pharmaceutical processes. Role of automation in improving the quality of the products while reducing costs; Ability of automation in improving speed, increased accuracy, and heightened process efficiencies; Infiltration of automation in areas...

  • Pursuing Efficiency: New Developments in Cleaning Technology. Chiarello-Ebner, Kaylynn // Pharmaceutical Technology;Mar2006, Vol. 30 Issue 3, p52 

    The article reports on developments in cleaning technology. It features analytical tools and methods that require less water and detergent. The article emphasizes the importance of cleaning verification of manufacturing equipment in drug production. It also details the efforts of pharmaceutical...

  • Strategies for High Containment. Van Arnum, Patricia // Pharmaceutical Technology;Sep2012-Supplement, pS6 

    The article presents information on high-potency manufacturing in the pharmaceutical industry. The challenge for designing high-potency containment facility is stated to be finding appropriate level of containment. Proper initials design and engineering of a potent-compound handling facility is...

  • Quality by Design for Analytical Methods. Nethercote, Phil; Ermer, Joachim // Pharmaceutical Technology Europe;Oct2012, Vol. 24 Issue 10, p52 

    Adoption of quality-by-design (QbD) concepts in pharmaceutical development and manufacture is becoming increasingly well-established. QbD concepts are aimed at improving the robustness of manufacturing processes based upon adopting a systematic and scientific approach to development and...

  • Early Development GMPs for Stability An Industry Perspective (Part IV). Acken, Bruce; Alasandro, Mark; Colgan, Stephen; Curry, Paul; Diana, Frank; Li, Q. Chan; Li, Z. Jane; Mazzeo, Tony; Rignall, Andy; Tan, Z. Jessica; Timpano, Robert // Pharmaceutical Technology Europe;Oct2012, Vol. 24 Issue 10, p61 

    The authors, part of the International Consortium on innovation and Quality in Pharmaceutical Development (IQ Consortium), explore and define common industry approaches and practices when applying GMPs in early development. A working group of the consortium aims to develop a set of...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics